Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial
Endocrine · 31.08.2023 · 83 (1) · 227-241
DOI: 10.1007/s12020-023-03487-4 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Endocrine, online erschienen am 31.08.2023. Verfasst von Mingyu Liao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Translational Research Key Laboratory for Diabetes, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China. Hauptthemen laut MEDLINE: Metformin, Polycystic Ovary Syndrome, Insulin Resistance. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Natural Science Foundation, National Science Fund for Distinguished Young Scholars.
Abstract (Originalsprache)
Purpose
Polycystic ovary syndrome (PCOS) is characterized by reproductive dysfunctions and metabolic disorders. This study aims to compare the therapeutic effectiveness of glucagon-like peptide-1 receptor agonist (GLP-1RA) + Metformin (Met) versus cyproterone acetate/ethinylestradiol (CPA/EE) + Met in overweight PCOS women and identify potential proteomic biomarkers of disease risk in women with PCOS.
Methods
In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day: 2 mg cyproterone acetate and 35-μg ethinylestradiol,) +Met (1500 mg/day) or GLP-1 RA (liraglutide, 1.2–1.8 mg/day) +Met (1500 mg/day) for 12 weeks. The clinical effectiveness and adverse effects were evaluated, followed by plasma proteomic analysis and verification of critical biomarkers by ELISA.
Results
Eighty(80%) patients completed the study. Both interventions improved menstrual cycle, polycystic ovaries, LH(luteinizing hormone) and HbA1c(hemoglobin A1c) levels after the 12-week treatment. GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI (Body Mass Index), and waist circumference, FBG(fasting blood glucose), AUCI(area under curve of insulin),TC (Total Cholesterol), IL-6(Interleukin-6) and improving insulin sensitivity, and ovulation in overweight women with PCOS, with acceptable short-term side effects. CPA/EE + Met was more effective in improving hyperandrogenemia, including T(total testosterone), LH, LH/FSH(Luteinizing hormone/follicle-stimulating hormone), SHBG(sex hormone-binding globulin) and FAI (free androgen index). By contract, GLP-1RA+Met group only improved LH. Plasma proteomic analysis revealed that the interventions altered proteins involved in reactive oxygen species detoxification (PRDX6, GSTO1, GSTP1, GSTM2), platelet degranulation (FN1), and the immune response (SERPINB9).
Conclusions
Both CPA/EE+Met and GLP-1RA + Met treatment improved reproductive functions in overweight PCOS women. GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI, and waist, and improving metabolism, and ovulation in overweight women with PCOS, with acceptable short-term side effects. CPA/EE + Met was more effective in reducing hyperandrogenemia. The novel plasma biomarkers PRDX6, FN1, and SERPINB9, might be indicators and targets for PCOS treatment.
Trial registration
ClinicalTials.gov Trial No: NCT03151005. Registered 12 May, 2017, https://clinicaltrials.gov/ct2/show/NCT03151005 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Translational Research Key Laboratory for Diabetes, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
- Department of Endocrinology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210016, China.
- Key Laboratory of Genetic Network Biology, Collaborative Innovation Center of Genetics and Development, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, 100101, Beijing, China.
- Univeristy of Chinese Academy of Sciences, 100049, Beijing, China.
- Department of Endocrinology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China.
- Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, TX, USA. zheng.sun@bcm.edu.
ORCID-Profile: Min Long
Förderung
- Chongqing Natural Science Foundation
- National Science Fund for Distinguished Young Scholars
Zitieren
APA
Liao, M., Li, X., Zhang, H., Zhou, L., Shi, L., Li, W., Shen, R., Peng, G., Zhao, H., Shao, J., Wang, X., Sun, Z., Zheng, H., & Long, M. (2023). Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial. Endocrine, 83(1), 227-241. https://doi.org/10.1007/s12020-023-03487-4
Vancouver
Liao M, Li X, Zhang H, Zhou L, Shi L, Li W, et al. Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial. Endocrine. 2023;83(1):227-241. doi:10.1007/s12020-023-03487-4
BibTeX
@article{Liao2023,
author = {Liao, Mingyu and Li, Xing and Zhang, Hao and Zhou, Ling and Shi, Liu and Li, Weixin and Shen, Rufei and Peng, Guiliang and Zhao, Huan and Shao, Jiaqing and Wang, Xiujie and Sun, Zheng and Zheng, Hongting and Long, Min},
title = {Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial},
journal = {Endocrine},
year = {2023},
volume = {83},
number = {1},
pages = {227--241},
doi = {10.1007/s12020-023-03487-4}
}
EUVIMED